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Summary
The primary goal of treatment for post-menopausal
osteoporosis (PMO) is reduction in fracture risk.
Therefore, clinicians must recommend therapies
that are safe and have proven anti-fracture efficacy.
Bisphosphonates have long been established as
first-line therapy for osteoporosis and several of
these drugs significantly reduce osteoporotic frac-
ture risk. However, choosing among different
bisphosphonates can represent a difficult clinical
decision. This review outlines the pharmacology of
various bisphosphonates, discusses how their
pharmacological characteristics affect their efficacy,
and summarizes clinical safety and efficacy data.
Clinical trial data and the opinions of expert
bodies suggest that alendronate, risedronate, iban-
dronate and zoledronic acid all provide fracture pro-
tection for patients with PMO. However, there are
differences among these agents. For example,
all four agents have demonstrated efficacy in
preventing vertebral fractures, but only zoledronic
acid and risedronate significantly reduce non-
vertebral fracture risk in pivotal trials. Moreover,
reduction in hip fracture risk has only been estab-
lished for alendronate, risedronate and zoledronic
acid. Current data suggest that ibandronate and
zoledronic acid have the most persistent antifracture
effect. Bisphosphonates have been associated with
a number of side effects, the evidence for which
is summarized in this review. The most pertinent
of these when choosing a bisphosphonate for
a particular patient are the well-documented
associations between gastrointestinal adverse
events and oral administration, and between acute
phase reactions and intravenous administration.
Ultimately, selection of a specific bisphosphonate
for treatment of PMO should be based on efficacy,
risk profile, cost-effectiveness and patient
preference.
Introduction
The primary goal of treatment for post-menopausal
osteoporosis (PMO) is to reduce the risk of fracture.1
This aim is reflected in the most recent guide-
lines on the evaluation of medicinal products in
the treatment of primary osteoporosis issued by the
European Medicines Agency’s Committee for
Medicinal Products in Human Use.2 This document
makes it clear that reduction in fracture risk is the
only endpoint that is acceptable in drug registration
studies, and that this should be demonstrated for
both spinal and non-spinal fractures. Non-spinal
fractures are specified as either femoral (hip) frac-
tures or major non-vertebral fractures (pelvis, distal
femur, proximal tibia, ribs, proximal humerus,
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forearm and hip). Bone mineral density (BMD) is
acceptable as the primary end point in bridging stu-
dies or as a secondary efficacy endpoint in pivotal
trials, but it is not an appropriate surrogate for frac-
ture reduction.2
Post-menopausal women at increased risk of frac-
ture are typically chosen as the population for the
pivotal studies associated with registration of a new
chemical entity. Once this registration has been
achieved, an extension of the indication may be
granted on the basis of bridging studies that dem-
onstrate non-inferiority of a new dose, route of
administration or formulation. Changes in BMD
are acceptable as the primary endpoint in such brid-
ging studies, and in those that aim to demonstrate
the efficacy of the drug in a different population
(e.g. men with osteoporosis).2
Evidence-based medicine should be the greatest
influence on the clinician’s approach to treatment.
There are two principles of evidence-based medi-
cine. First, there is a hierarchy of evidence in
which greater emphasis is given to consistent find-
ings from randomized controlled trials (RCTs).
Second, evidence is never enough to make clinical
decisions; it should be combined with clinical judg-
ment and the patients’ preferences and values. The
current availability of highly efficacious bisphospho-
nates coupled with well-conducted studies allows
the principles of evidence-based medicine to be
applied to the treatment of PMO. These in turn
allow rational choices to be made for the individual
patient. A number of different methodologies exist
for assessing the evidence base; first, to ensure that
the scientific evidence is applicable to real clinical
practice, and second, to highlight any significant
gaps in the evidence.
Making appropriate treatment decisions can
be a complex process. Bisphosphonates are a
long-established first-line therapy for osteoporosis
and other conditions such as glucocorticoid-
induced osteoporosis, Paget’s disease and hypercal-
cemia of malignancy. In recent years, attempts to
improve anti-fracture efficacy, moderate side effects
and provide optimal convenience to patients have
led to the development of newer bisphosphonates,
including those that can be administered with longer
inter-dosing intervals. For PMO, nitrogen-containing
bisphosphonates are currently considered the treat-
ment of choice.1 These agents increase BMD, and
most have been shown to provide fracture protec-
tion in RCTs.1
The RAND (Research and Development) appro-
priateness method is generally regarded as the
most rigorous and systematic methodology.3,4 The
RAND method rates the appropriateness of medical
interventions using the opinions of experts. The
justification for this approach is that RCTs are
time-consuming and expensive, sample sizes are
limited, and they are conducted under ideal condi-
tions; hence the results are generalized and should
be treated as such. By utilizing the knowledge and
experience of expert physicians (much of which is
derived from RCT data), the principle is that the
RAND method can provide a detailed assessment
about the appropriateness of a treatment.5
In 2007, the RAND evidence-based practice
centre prepared a comparative effectiveness review
(CER) that compared the fracture reduction benefits
among and within classes of treatment for patients
with low bone density. They concluded that there
is good evidence from RCTs that, compared with
placebo, alendronate, ibandronate, risedronate
and zoledronic acid prevent vertebral fractures,
and risedronate and alendronate prevent both
non-vertebral and hip fractures. There is also good
evidence that zoledronic acid prevents
non-vertebral fractures.5
In addition to RAND publications, clinicians
can utilize information from the World Health
Organization (WHO) to review the evidence base.
WHO publishes a series of technical reports that
contain the latest scientific and technical advice
on a broad range of medical and public health sub-
jects based on the findings of various international
groups of experts.6
More recently, the Scientific Advisory Board of
the European Society for Clinical and Economic
Evaluation of Osteoporosis and Osteoarthritis
(ESCEO) and the International Osteoporosis
Foundation (IOF) have jointly published guidance
on the diagnosis and management of PMO.7 These
experts concluded that alendronate and risedronate
reduce the risk of vertebral fracture in patients with
osteoporosis. This protection has been established
both in patients who do and in those who do not
have a vertebral fracture prior to treatment.
Alendronate and risedronate also reduce the risk of
non-vertebral fractures, including those of the hip, in
patients with a prior vertebral fracture. A similar
clinical profile has been established for zoledronic
acid, with the exception that evidence for
non-vertebral fracture protection has been estab-
lished only in a mixed group of patients (i.e. those
with or without prevalent vertebral fractures).
Ibandronate has been shown to provide vertebral
fracture protection in patients with a prior vertebral
fracture. The ibandronate evidence base for
non-vertebral fracture protection is limited to subsets
of the population and has been suggested only
in post hoc analyses. None of these four agents
has been shown to be effective in preventing
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non-vertebral fractures in patients with osteoporosis
who do not have a vertebral fracture at baseline.7
Based on the RAND, WHO and ESCEO/IOF rec-
ommendations, it would appear that alendronate,
risedronate and zoledronic acid all provide various
types of fracture protection, and ibandronate verte-
bral fracture protection, for patients with PMO. A
clinician presented with this evidence alone may
therefore ask themselves whether either patient sat-
isfaction or outcome is affected by the choice of
bisphosphonate.
This article aims to address this question by look-
ing at bisphosphonates from a number of different
perspectives. We will explore how pharmacological
differences among these drugs affect their potency
and bioavailability, and whether these characteris-
tics translate into differences in clinical efficacy.
We will also examine the differences in clinical
trial design and endpoints that add to the complexity
of interpreting and comparing reported results.
Differences in the safety of bisphosphonates are
also considered, as this issue often wields a substan-
tial influence on patient choice and preference.
Based on these considerations, we aim to aid clin-
icians in the complex decision-making process
involved in choosing a bisphosphonate therapy,
and hope to facilitate a true evidence-based ap-
proach to PMO management, with an optimal out-
come for all patients.
Distinguishing among
bisphosphonates based on
pharmacology
Chemical composition and implications
All of the commonly used bisphosphonates are
characterized by two phosphate groups sharing a
common carbon atom (Figure 1). The P–C–P back-
bone is responsible for the bisphosphonates’ strong
affinity for hydroxyapatite, and helps to effect the
potent inhibition of bone metabolism that is charac-
teristic of the bisphosphonate class.8 Both of the
phosphate groups are important, because altering
either or both diminishes both the agent’s affinity
for hydroxyapatite and its biochemical potency
(Figure 2a and b).8,9 The R1 chain is typically a hy-
droxyl (OH) group, and this enables the agent to
bind strongly to calcium. The composition of the
R2 chain, in contrast, varies widely among bispho-
sphonates, and it is this that determines the agent’s
anti-resorptive potency. The anti-resorptive action of
nitrogen-containing bisphosphonates results from
their effects on the mevalonate pathway and, in par-
ticular, the enzyme farnesyl pyrophosphate synthase
(FPPS) (Figure 2c).10 The most potent bisphospho-
nates have an R2 chain containing a nitrogen atom
(e.g. pamidronate, alendronate, risedronate, iban-
dronate, zoledronic acid). More potent still are
those containing a nitrogen atom within a hetero-
cyclic ring (e.g. risedronate and zoledronic acid)
(Figure 2a).8
Bioavailability
The bioavailability of bisphosphonates has been
determined by measuring the 24-h urinary excretion
of drug after a single intravenous (IV) dose. The re-
mainder is the amount retained by the skeleton. The
bioavailability of bisphosphonates is generally cor-
related with their affinity for bone mineral. Thus, of
the nitrogen-containing bisphosphonates, risedro-
nate is the least bioavailable (65% excreted in the
urine),11 followed by ibandronate (50–60%),12 alen-
dronate (44%)13 and zoledronic acid (38%).14
The mode of administration of the bisphospho-
nate has a considerable effect on its absorption. As
a class, bisphosphonates are poorly absorbed from
the gastrointestinal tract. For example, when oral
bisphosphonates such as alendronate and risedro-
nate are administered, <1% of the dose is typically
absorbed, regardless of the dose given.15 To maxi-
mize absorption, it is generally recommended that
oral agents are taken on an empty stomach with
plain water and that the patient fast for at least
Figure 1. The chemical structure of bisphosphonate.
The figure shows the structure of a generic bisphospho-
nate. Bisphosphonates’ high affinity for bone is conferred
by the phosphonate–carbon–phosphonate (P–C–P) back-
bone. This affinity can be enhanced by placement of
a hydroxyl group in the R1 position. The anti-resorptive
potency of the drug is determined by the structure of the
R2 side chain.
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30min afterwards. Patients are also instructed not to
lie down for 30min after taking the tablet. In the
case of oral ibandronate, it is recommended that
the patients neither eat nor lie down for 60min
after treatment administration.12 It is important that
patients comply with the instruction to fast for
60min because a 48-week, oral ibandronate
non-inferiority study that evaluated the effects of
30- and 60-min post-treatment fasts on BMD con-
cluded that reducing the post-dose fasting interval
was associated with significant reductions in BMD
gains.16
Many patients find the need for such fasting on a
daily or even weekly basis to be inconvenient.
Figure 2. (a) Structure and relative potency of bisphosphonates.94 Relative potency at inhibiting bone resorption in rats as
compared with etidronate. The majority of the bisphosphonates that have been used in humans have a hydroxyl group in the
R1 position. The R2 side chain is more variable in structure. (b) HAP adsorption affinity constants for the bisphosphonates
under experimental conditions of growth (adapted from Nancollas et al.8). The data represent the mean SD. Experiments
were performed at pH 7.4 and were initiated by the introduction of known amounts of HAP crystallites to a solution of
calcium chloride and potassium dihydrogen phosphate in sodium chloride. The low KL (adsorption affinity constant) for
clodronate is attributed to the absence of a hydroxyl position in the R1 position. Since all other bisphosphonates shown on
the graph do have a hydroxyl in this position, it is evident that the configuration of the R2 group also influences binding to
HAP. Reproduced with permission from Elsevier. Nancollas et al.8 (c) Inhibition of FPPS by bisphosphonates (adapted from
Dunford et al.10). ALN: alendronate; CLOD: clodronate; ETID: etidronate; HAP, hydroxyapatite; IBAN: ibandronate; RIS,
risedronate; ZOL, zoledronic acid; FPPS: farnesyl diphosphate synthase; PAM: pamidronate; NS: not statistically significant.
A bacterial lysate containing recombinant human FPPS was preincubated with 0.1mM bisphosphonate for 10min before
addition of substrate (14C isopentenyl diphosphate). The data represent the mean SE of the mean of at least three inde-
pendent experiments, expressed as a percentage of FPPS activity in the absence of bisphosphonate. ***P<0.001 vs. control.
*P<0.05 vs. ALN. **P<0.001 vs. ALN (analysis of variance with Bonferroni’s post hoc test). Reproduced with permission
from the American Society for Pharmacology and Experimental Therapeutics.8
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Intravenous administration of bisphosphonates (al-
though also considered inconvenient by some) has
been introduced in recent years to overcome
this problem. When compared with oral dosing, IV
administration has the added benefit of limiting sys-
temic exposure. For example, neither IV ibandro-
nate nor IV zoledronic acid are metabolized with
50 and 62% principally bound to bone tissue, re-
spectively. The remainder of the administered dose
is excreted unchanged via the urine.12,14
These data demonstrate how the bisphospho-
nates, despite possessing identical core structures,
differ widely in their affinity for bone mineral,
anti-resorptive potency and bioavailability. These
differences are due to variations in their structure
and mode of administration. In this sense, all
bisphosphonates are definitely not the same. But
do these largely imperceptible differences actually
influence the clinical profile of bisphosphonates in
the treatment of PMO? And are there any real, tan-
gible differences among these drugs in anti-fracture
efficacy?
Distinguishing among
bisphosphonates based on clinical
trial results in PMO
Pivotal placebo-controlled trials have demonstrated
the efficacy of bisphosphonates in improving BMD
at key skeletal sites, and have provided information
on reducing the risk of bone fracture.17–20 In these
trials, bisphosphonates consistently show an ability
to increase BMD at key skeletal sites, particularly at
the lumbar spine. When compared with placebo,
mean improvements in the BMD of the lumbar
spine of 6.2–6.6% have been observed with daily
alendronate,17,20 5.4–5.9% with daily risedro-
nate,21,22 5.2% with daily ibandronate19 and 6.7%
with once-yearly zoledronic acid.18 The ability to
improve BMD at other sites is more variable. For
example, mean improvements in femoral neck
BMD of 4.1–4.6 and 5.06% have been observed
with daily alendronate17,20 and with once-yearly
zoledronic acid, respectively;18 but mean improve-
ments of just 1.6–3.1% have been seen with daily
risedronate21,22 and 3.4% with daily ibandronate.19
Femoral neck BMD provides a robust surrogate
marker of the risk of hip fracture. However, reduc-
tion of fracture risk at vertebral and non-vertebral
sites is the most important clinical outcome of
treatment with bisphosphonates. Interpretation of
such results across trials with different agents is
problematic because comparative data are limited.
Differences in bone affinity and bioavailability
among agents might be expected to result in differ-
ences in clinical outcome, but comparison of trials
using different agents is hampered by heterogeneity
in patient populations and, in some cases, limita-
tions of trial design.
A number of investigators have attempted to over-
come the paucity of comparative data. For example,
Rosen et al.23 carried out a 12-month, randomized,
double-blind trial that compared the effects of alen-
dronate and risedronate (both administered once
weekly) in women with PMO. These investigators
found that alendronate was associated with signifi-
cantly greater gains in BMD and reductions in mark-
ers of bone turnover than risedronate. However, the
relative effects of these two treatments on fracture
incidence were not assessed, and this study thus
does not provide us with the data that we need to
make a definitive comparison between these two
treatments.
A study comparing the effects of a single dose
of zoledronic acid with weekly alendronate in
post-menopausal women with osteoporosis
showed markers of bone resorption were significant-
ly reduced at Weeks 1, 2, 4, 8, 12 and 24 after
zoledronic acid treatment compared with alendro-
nate. A significant difference between the two treat-
ments for markers of bone formation was observed
at Week 12 but not Weeks 4 or 24. In this study, the
effects of either treatment on BMD or fracture inci-
dence were not assessed and so direct comparisons
in fracture efficacy between the treatments are not
possible.24
Other attempts to generate meaningful com-
parisons among agents have included use of
post-marketing surveillance data. For example,
eValuation of ibandronate efficacy (VIBE) was a
retrospective, observational claims database study
that used eligibility, pharmacy claims and medical
claims data to compare fracture rates between
female patients treated with monthly ibandronate
(n=7345) and those receiving weekly oral alendro-
nate or risedronate (n = 56 837).25 The incidences of
hip fracture, non-vertebral fracture and any clinical
fracture were similar in the two groups of patients.
However, the risk of vertebral fracture was signifi-
cantly lower in the ibandronate-treated patients than
in those who received weekly alendronate/risedro-
nate [relative risk, 0.36, 95% confidence interval
(95% CI): 0.18–0.75].
Post-marketing surveillance data were also used
in the RisedronatE and ALendronate (REAL) cohort
study, a retrospective comparison of the anti-fracture
efficacy of once-weekly alendronate and risedronate
in women aged 565 years that was based on
health-care utilization records.26 In this study, the
12-month incidences of non-vertebral and hip
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fractures were significantly lower in the
risedronate-treated group than in the alendronate
group (non-vertebral fractures: 2.0% vs. 2.3%;
P=0.03; hip fractures: 0.4% vs. 0.6%; P=0.01).
Another potential strategy to compare the efficacy
of different bisphosphonates has been to calculate
the number needed to treat (NNT) from each of the
pivotal trials. The NNT is the number of patients
who need to be treated with a drug over a fixed
period of time to prevent the occurrence of one
event, such as a fracture. It is the inverse of the ab-
solute risk reduction. In a recently published ana-
lysis of treatment efficacy by NNT, zoledronic acid
treatment was associated with an NNT of 14 for
prevention of vertebral fracture over 3 years.27
Alendronate, risedronate and zoledronic acid ap-
peared to have similar influence on hip fracture
with an NNT of 91 for each drug.27 NNT depends
mainly on the severity of the disease in the recruited
population, hence fracture risk in the placebo group.
For instance, NNTs for the same agent could be
markedly different if determined in patient groups
at low vs. high risk of fracture.28 Thus, as a measure
with which to compare treatments, NNT should be
interpreted with caution.
Comparisons of outcomes based on post-
marketing data and calculations of NNT may have
a place in the medical evidence base, but they
cannot replace well-designed, randomized,
double-blind controlled trials. Table 1 summarizes
the designs of the pivotal RCTs that have been per-
formed to determine the efficacy and safety of
bisphosphonates, and highlights the similarities
and differences among studies.17–22,29,30 It is evident
from the table that there are key differences among
studies, particularly in terms of severity of disease at
baseline and whether prior fracture was an inclusion
criterion, an exclusion criterion, or neither. Trials
were similar with regard to the mean age of patients.
In terms of the alendronate trials, this would indicate
that, of the patients previously treated in the fracture
intervention trials (FIT)-1 and FIT-2, older patients
were less likely to receive treatment in the fracture
intervention trial long-term extension (FLEX) be-
cause of loss to the study or exclusion. In addition,
patients in different trials received different regimens
of calcium/vitamin D therapy, and in most cases this
was given according to baseline parameters within
each arm. The health outcomes and reduction in
osteoporosis with zoledronic acid once-yearly piv-
otal fracture trial (HORIZON-PFT) incorporated a
formal stratification made according to whether
patients were taking osteoporosis medications at
baseline (21% of patients in each arm). Table 1
also shows variation in discontinuation rates
among trials using daily regimens. Discontinuation
is a particular issue with long-term daily oral
therapy.
Most trials have assessed incidence of morpho-
metric vertebral fractures as an endpoint. Morpho-
metric vertebral fractures are radiographically
confirmed fractures that cause a protocol-defined
decrease from baseline in vertebral height. This de-
crease in height may be defined as a percentage
change (e.g.520 or515%) or an as absolute meas-
urement (e.g. 54mm). Some investigators use a
semiquantitative grading system in addition to, or
instead of, a quantitative system. The most widely
used grading scheme has four categories that range
from 0 (normal) through 1 (mild deformity, 20–25%
reduction in height), 2 (moderate deformity,
25–40% reduction) and 3 (severe deformity, 40%
reduction).31 This grading system relies on visual
inspection.
A range of criteria for diagnosis of incident verte-
bral fractures was used in the studies summarized in
Tables 1 and 2. These included quantitative criteria
only, semiquantitative criteria only and a mixture of
the two systems. Moreover, the quantitative criteria
varied among studies (520% and54mm decrease
in vertebral height in alendronate trials; 515% de-
crease in risedronate trials). The European
Medicines Agency’s guideline on the evaluation of
medicinal products in the treatment of primary
osteoporosis specifies only that ‘a carefully validated
method with predefined criteria for diagnosis of frac-
tures’ should be used for assessment of vertebral
fractures.2 However, it is self-evident that differ-
ences among studies in the criteria used may affect
the results. For example, higher diagnostic sensitiv-
ity but more false positives are achieved when frac-
ture is defined as a reduction in vertebral height of
515% than when the criterion is a reduction in
height of 520%.32
Some trials have also assessed incidence of clin-
ical fractures (vertebral or non-vertebral) as second-
ary endpoints. These are identified symptomatically
and reported as adverse events. Comparing the in-
cidence of non-vertebral fractures among trials is
particularly problematic because their definition
varies, with several studies defining these fractures
according to occurrence at just six sites, and others
including almost all non-vertebral fractures (typical
exceptions include fractures due to excessive
trauma, and those involving the hands, feet, face
and skull; Table 1, 2). Non-vertebral fractures are
infrequent clinical events and non-vertebral fracture
reduction as a primary endpoint in clinical trials re-
quires relatively high-risk patients and very large
study samples. Similarly, accurate determination of
hip fracture rates also requires highly powered stu-
dies. Direct comparisons of clinical trial results
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should therefore be made with caution. It should
also be noted that, with regard to daily bisphospho-
nate regimens, the required dosing over time may
not be achieved in clinical practice, due to poor
compliance.
In the FIT-1 and -2 studies, the 3- and 4-year risk
reduction achieved with alendronate for morpho-
metric vertebral fractures reached significance
(P4 0.001 in each study; Table 2). Significant risk
reduction for clinical vertebral fractures was also
reported in FIT-1 (P4 0.001). However, the risk re-
duction did not reach significance for non-vertebral
fractures (FIT-1, P=0.063; FIT-2, P=0.13), was just
significant for hip fractures in FIT-1 (P=0.047), and
not significant in FIT-2 (P=0.44). It should be noted
that these studies were underpowered to assess
these secondary endpoints. Limited benefit was
seen with long-term alendronate therapy. In the
FLEX extension study, the risk reduction for mor-
phometric vertebral fractures was only 14% over
years 5–10,29 and this did not reach clinical signifi-
cance (P-value not provided). These findings were
supported by changes in markers of bone turnover
such as alkaline phosphatase, C-telopeptide of type
I collagen, and N-terminal propeptide of type I col-
lagen, which declined during FIT-1 and remained
relatively constant during FLEX. While benefits were
not apparent for most endpoints, a significant risk
reduction for clinical vertebral fractures was
observed (5.3% with placebo vs. 2.4% with alen-
dronate, relative risk reduction 55%) and women
with a history of repeated clinical vertebral fractures
may benefit from extended bisphosphonate therapy.
In the two key trials using risedronate that were
carried out in North America [Vertebral Efficacy
with Risedronate Therapy (VERT-NA)] and world-
wide (VERT-MN), risedronate 5mg significantly
reduced the risk of new vertebral fractures
(P=0.003 and <0.001, VERT-NA and VERT-MN, re-
spectively) and non-vertebral fractures (P = 0.02 and
0.06, VERT-NA and VERT-MN, respectively). Hip
fracture was not a primary endpoint in either of
these studies and neither study was powered to
assess this endpoint. However, in the Risedronate
Hip Intervention Programme (Risedronate-HIP), al-
though hip fracture risk reduction did not reach sig-
nificance in patients aged 580 years, the risk
reduction was 40% (P=0.009) in the cohort of
women aged 479 years who had osteoporosis at
baseline.
In the oral iBandronate Osteoporosis vertebral
fracture trial in North America and Europe (BONE),
ibandronate significantly reduced the risk of mor-
phometric vertebral fracture when used daily
(P=0.0001) or intermittently (P=0.0006). A signifi-
cation risk reduction was also seen for clinical
vertebral fractures when ibandronate was used
daily (P=0.0117) or intermittently (P=0.0143), but
reductions in non-vertebral fractures were not sig-
nificant in either treatment arm.
In the HORIZON-PFT, zoledronic acid 5mg sig-
nificantly reduced the risk of morphometric verte-
bral fractures (P<0.001), non-vertebral fractures
(P<0.001) and hip fractures (P=0.002). The risks
of other secondary fracture end points (all clinical
fractures and clinical vertebral fractures) were also
reduced in the zoledronic acid group (reductions of
33 and 77%, respectively; P<0.001 for both).
Assessment of markers of bone turnover in
the HORIZON-PFT and VERT-MN indicated that
effects occur early with a marked decline in the
first 6 months and maintenance of this effect
thereafter.18,22
These data indicate that all of the bisphospho-
nates demonstrate efficacy in preventing vertebral
fractures (Table 2), although it should be noted
that patients with more severe disease (i.e. those
with baseline vertebral fractures) were not included
in the FIT-2 trial (Table 1). Ibandronate and zoledro-
nic acid demonstrated the most persistent
anti-fracture effect over time. The alendronate and
zoledronic acid trials were both adequately pow-
ered to establish that treatment can reduce the
risk of hip fractures (Table 2). Only zoledronic
acid and risedronate significantly reduced the risk
of non-vertebral fractures; this effect was not seen
with alendronate or ibandronate treatment in the
FIT-1/2 and BONE trials (Table 2).
Distinguishing among
bisphosphonates based on
safety data
As a class, bisphosphonates are associated with a
number of side effects. Mode of administration has
a major influence on the incidence of some of these
adverse events. This is most notable for gastrointes-
tinal adverse events (which predominate after oral
administration) and infusion reactions (which pre-
dominate after IV administration). The following dis-
cussion uses standard designations to describe the
incidence of side effects: very common (affects more
than 1 user in 10); common (affects 1 to 10 users in
100); uncommon (affects 1 to 10 users in 1000); rare
(affects 1 to 10 users in 10 000); very rare (affects <1
user in 10 000).
Gastrointestinal side effects
Gastrointestinal side effects that may occur after oral
administration include dysphagia, oesophagitis and
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oesophageal or gastric ulcers, all of which have
been reported after use of ibandronate, risedronate
and alendronate.21,22,33–35 Clinical trials involving
administration of ibandronate (150mg monthly or
2.5mg daily) describe oesophagitis, gastritis,
gastro-oesophageal reflux disease, dyspepsia, diar-
rhoea, abdominal pain and nausea as common
events, whereas oesophageal ulcerations, oesopha-
geal strictures, dysphagia, vomiting and flatulence
are classified as uncommon.12 Clinical trials using
alendronate have reported similar rates of upper
gastrointestinal adverse events to those seen with
oral placebo.36 Local irritation of the upper gastro-
intestinal mucosa is believed to underlie the associ-
ation between these events and bisphosphonate
administration.12 Gastrointestinal adverse events
are also common after IV administration of bispho-
sphonates, but the incidence is similar in bispho-
sphonate- and placebo-treated patients.37
It has been proposed that the gastrointestinal ad-
verse events observed in association with bispho-
sphonate use may be related to the ability of these
drugs to inhibit the enzyme FPPS, the action that
produces their anti-resorptive efficacy. An in vitro
study of the effects of alendronate and risedronate
on normal human epidermal keratinocytes (NHEK),
a model system of squamous epithelium of the type
that covers the oesophagus, showed that both
bisphosphonates inhibited growth of NHEKs without
inducing apoptosis. The concentrations at which
growth was inhibited were similar to those that
might occur in oesophageal reflux after clinical
dosing.38
For all oral bisphosphonates, an important way to
minimize the risk of gastrointestinal adverse events
is by using a stringent administration regimen. The
typical dosing regimen specifies that tablets are
taken on an empty stomach with 200ml (6–8 fluid
ounces) of water and, as described previously, pa-
tients must fast and remain upright for at least 30min
(Table 3) to avoid epigastric pain. Failure to observe
these precautions can expose patients to events such
as oesophagitis, mucositis, nausea, vomiting and
diarrhoea.
Acute phase reactions
An ‘acute phase reaction’ characterized by myalgia,
arthralgia, fever, flu-like symptoms and mild
headache is common/very common after IV admin-
istration of bisphosphonates.37 The mechanism
underlying this symptom complex is not fully under-
stood but is thought to involve direct and indirect
stimulation of gdT cells, which may lead to
increased circulating levels of interleukin-6 and
tumour necrosis factor-a.39 The indirect stimulation
of gdT cells may be the result of the inhibition of
FPPS by nitrogen-containing bisphosphonates and
in vitro studies have shown that the potency of in-
dividual bisphosphonates to inhibit FPPS directly
correlates with their ability to stimulate gdT cells.
Inhibition of FPPS causes the accumulation of iso-
prenoid lipids, upstream of FPP in the mevalonate
pathway, which then stimulates the proliferation
and activation of gdT cells.40
Symptoms of the acute phase reaction can be
reduced with over-the-counter anti-inflammatory
medications and usually resolve within 3 days of
onset.12,18,41 All aspects of the acute phase reaction
become substantially less frequent following the first
dose. For example, in the HORIZON-PFT, the net
rate (zoledronic acid minus placebo) of the acute
phase reaction was 30% after the first dose, but
7 and 3% after the second and third infusions, re-
spectively.42 Transient, flu-like symptoms with IV
ibandronate given every 3 months are also typically
associated with the first injection only.12
Acute phase reactions are typically reported in
association with IV administration of bisphospho-
nates but are also described as common after
monthly oral administration of ibandronate and as
rare after daily and weekly oral administration of
alendronate.12,33
Cardiac side effects
Both oral and IV bisphosphonates have been asso-
ciated with increased incidence of atrial fibrillation
(AF). For example, secondary analyses of data from
the Fracture Intervention Trial have suggested a
greater risk of serious AF adverse events with alen-
dronate than with placebo (1.5% vs. 1.0%).43
Similarly, in the HORIZON-PFT, serious AF was
more frequent in patients who received IV zoledro-
nic acid than in those who received placebo (1.3%
vs. 0.5%; P<0.001).18 However, subsequent exten-
sive analyses of other RCTs involving zoledronic
acid, including the HORIZON-recurrent fracture
trial (RFT),41 failed to demonstrate an increase in
risk for AF. Moreover, a recent analysis of new
data from the HORIZON-PFT/RFT trials found the
increase in the risk of AF or atrial flutter with zole-
dronic acid treatment to be non-significant (hazard
ratio = 1.25, P=NS). The only treatment-factor inter-
action that was statistically significant was age
[HR=0.963, P<0.067 (significance threshold,
P<0.10)]. This interaction could be due to a greater
increase in risk with age in the placebo group than
in the zoledronic acid group (difference in risk be-
tween patients aged 75–84 years and those 585
years: placebo, 2.7%; zoledronic acid, 1.9%).44
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It has been suggested that the conflicting data on
AF risk in the HORIZON studies, with an increased
incidence seen in HORIZON-PFT, could be an arte-
fact induced by the multiple comparisons.45 In the
HORIZON-PFT, in 47 of the 50 zoledronic-acid
treated patients with an adjudicated serious adverse
event of AF, the event occurred >30 days after infu-
sion, by which time zoledronic acid is undetectable
in the circulation.18 The link between oral alendro-
nate administration and serious AF adverse events
has also been called into question by the results of a
recent population-based case–control study invol-
ving data from 13586 patients with AF or atrial flut-
ter and 68 054 controls.46 The adjusted relative risk
for these conditions associated with current use of
bisphosphonates (etidronate or alendronate) was
0.95 (95% CI: 0.84–1.07), thus refuting the sugges-
tion that oral bisphosphonates increase the risk of AF
or atrial flutter.
To date, no convincing mechanism has been pro-
posed to account for the potential association be-
tween bisphosphonate use and risk of AF, and no
effect of dose or duration of therapy on the inci-
dence of AF has been shown.47 These findings,
combined with the clinical trial data, led the
United States Food and Drug Administration (FDA)
to conclude in 2008 that there is no clear associ-
ation between overall bisphosphonate exposure and
the rate of serious or non-serious AF and that
health-care professionals should not alter their
bisphosphonate prescribing patterns on the basis of
this purported association.48
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) has been reported as
a complication of both oral and IV bisphosphonate
administration. Most cases have occurred in oncol-
ogy patients who have received high-dose IV
bisphosphonates as part of their chemotherapy,
although the condition has also been reported in
patients with benign bone diseases such as PMO
or Paget’s disease. Current risk estimates for
bisphosphonate-associated ONJ in osteoporosis pa-
tients range from 1 per 20 000 to 1 per 100 000
patient-years.49–51 However, it is difficult to make
accurate frequency estimates because ONJ remains
a poorly defined condition. In the HORIZON-PFT
(the only bisphosphonate clinical trial to have
included adjudication for ONJ), this condition was
reported in one patient treated with zoledronic acid
and one patient who received placebo (incidence of
0.026% for both). Both patients recovered.18,52
Osteonecrosis of the jaw is also very rare after oral
administration of bisphosphonates. The low inci-
dence of this event is demonstrated by the results
of a 2009 systematic review that identified 1850
cases of ONJ in 92 publications between 1966
and 26 January 2008. Of these, only 59 cases
(3.2%) involved the use of oral bisphosphonates
(alendronate, clodronate or risedronate), with the re-
mainder involving treatment with IV ibandronate,
pamidronate or zoledronic acid.50
The pathogenesis of ONJ is poorly understood
and the mechanism for involvement of bisphospho-
nates—if any—is unknown. Alterations in angiogen-
esis or bone turnover, delayed epithelialization,
immunocompromise and infection have all been
proposed as causative factors, and a potential role
for bisphosphonates in many of these factors has
been proposed but not substantiated.52 A consensus
document that resulted from an expert meeting
convened by the ESCEO and the Foundation for
Research on Osteoporosis and other Bone
Diseases came to a number of conclusions, all of
which are relevant to clinicians who prescribe
bisphosphonates. The panel concluded that the in-
cidence of ONJ in patients taking bisphosphonates
for osteoporosis is very low, that the majority of ONJ
cases occur after tooth extraction, that there are no
data that unequivocally link the development of
ONJ to bisphosphonate intake in osteoporotic pa-
tients, and that the underlying risk of developing
ONJ may be increased in osteoporotic patients by
comorbid diseases and administration of immuno-
suppressive drugs.52
Atypical subtrochanteric fractures
In recent years, an association between atypical
fractures and long-term bisphosphonate therapy
has been reported in several clinical case reports
and case reviews. In particular, these involve frac-
tures of the subtrochanteric or diaphyseal femur,
predominantly following long-term oral alendronate
use.53–59 Secondary analysis of data from three
large, randomized bisphosphonate trials (FIT, FLEX
and HORIZON-PFT) identified fractures of the sub-
trochanteric or diaphyseal femur in 10 patients [six
bisphosphonate treated (0.077%), four placebo trea-
ted (0.053%)] and an overall incidence of 2.3 per 10
000 patient-years.60 Compared with placebo, the
relative hazard in bisphosphonate-treated patients
was 1.03 (95% CI: 0.06–16.46) for oral alendronate
use in the FIT trial, 1.50 (95% CI: 0.25–9.00) for IV
zoledronic acid use in the HORIZON-PFT trial,
and 1.33 (95% CI: 0.12–14.67) for continued oral
alendronate use in the FLEX trial. Black et al.60 con-
cluded that the incidence of fracture of the subtro-
chanteric or diaphyseal femur was very low, even
among women who had received bisphosphonate
therapy for 10 years, but that their study was
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underpowered to reach definitive conclusions re-
garding an association with bisphosphonate use.
Further insight is available from a recently pub-
lished systematic literature search of case/case series
studies that summarized data from 141 cases of
atypical femoral fracture in women who had been
treated with a bisphosphonate at a dosing regimen
suitable for the prevention or treatment of osteopor-
osis.61 This article, which defines these fractures
predominantly as insufficiency fractures, summar-
izes some of the clinical features that may allow
identification of the bisphosphonate-treated patients
who are at the greatest risk of developing atypical
fractures and shows that long-term bisphosphonate
therapy is not a prerequisite for their development. It
also highlights the use of glucocorticoids and proton
pump inhibitors as important risk factors.
A 2008 bisphosphonate class review by the
Committee for Medicinal Products for Human Use
(CHMP) concluded that there is an association be-
tween atypical stress fractures and long-term use of
alendronate, but uncertainty concerning the exist-
ence of a class effect.62 This led to a new special
warning/precaution being included on the alendro-
nate label that advised discontinuation of therapy in
patients with stress fracture pending performance of
an individual benefit-risk assessment.63 Possible
mechanisms by which alendronate may predispose
to atypical femoral fractures include accumulation
of microdamage/microfractures, decreased repair
and impaired healing in bone, suppression of
bone turnover, increased mineralization leading to
development of brittle bones, and inadequate min-
eralization.62 However, we do not know whether
these mechanisms apply to all nitrogen-containing
bisphosphonates and/or other strong resorption in-
hibitors. An association with atypical subtrochan-
teric fractures may only have been found for
alendronate thus far because it has been on the
market for longest, and therefore has the greater
volume of follow-up data available. A recently pub-
lished position statement by the European Society
on Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis, and International Osteoporosis
Foundation (ECCEO-IOF) Working Group con-
cluded that, although bisphosphonate use may be
associated with atypical subtrochanteric fractures,
the case thus far remains unproven.64
Bone pain
Bisphosphonates are widely used for the control of
bone pain in patients with cancer.65 However,
somewhat ironically, bone pain may also be a side
effect of bisphosphonate use. Such bone pain may
occur as part of the acute phase reaction that occurs
in some patients after IV administration of bispho-
sphonates or may occur as an uncommon isolated
symptom after oral administration of bisphospho-
nates.12 Placebo-controlled trials involving IV ad-
ministration of bisphosphonate to patients with
osteoporosis have shown that this adverse event is
of variable incidence, but may be common in both
zoledronic acid- and placebo-treated patients
(2-year post-low trauma hip fracture study: bone
pain recorded in 3.2 and 1.0% of zoledronic acid-
vs. placebo-treated patients, respectively; 3-year
study in PMO patients: bone pain recorded in 5.8
and 2.3% of patients, respectively).37
Renal dysfunction
Renal dysfunction is a known class effect of bispho-
sphonates and both oral and IV administration are
contraindicated in patients with severe renal impair-
ment.12,33,37,66 As a result, patients with creatinine
clearance of <30ml/min are usually excluded from
bisphosphonate clinical trials and the effects of
bisphosphonates on this group have not been quan-
tified. Trials involving zoledronic acid have
recorded a transient increase in serum creatinine
levels within 10 days of dosing in 1.8% of zoledro-
nic acid-treated patients and 0.8% of placebo-
treated patients, all of which resolved without
specific therapy.37 Moreover, a renal safety analysis
carried out as part of HORIZON-PFT found no
cumulative impact on renal function of long-term
(over 3 years) zoledronic acid administration and
no difference in mean calculated creatinine clear-
ance between zoledronic acid- and placebo-treated
patients.67 However, recent post-marketing data
from the FDA show that 24 evaluable cases of
renal impairment and acute renal failure associated
with use of zoledronic acid in osteoporosis and
Paget’s disease of bone were reported in the 17
months to February 2009. Fourteen of the 24 pa-
tients had underlying medical conditions associated
with risk of renal impairment or acute renal failure,
or had been exposed to nephrotoxic drugs. Many
patients improved following IV fluid administration
or other supportive care. Seven patients died, al-
though no association between zoledronic acid
use and these deaths has been established. Based
on these reports, the zoledronic acid label in the
USA has been updated to include data on acute
renal failure and advice for physicians, with recom-
mendations that serum creatinine should be moni-
tored before and after each infusion in patients with
pre-existing renal compromise or other risk factors
such as concomitant nephrotoxic medications or di-
uretic therapy.68
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The mechanism by which bisphosphonates cause
renal compromise has not been established. Renal
precipitation of bisphosphonate aggregates or cal-
cium complexes has been suggested, but is poorly
supported by preclinical studies.69 In nitrogen-
containing bisphosphonates, the adverse effect on
renal function may be mediated via inhibition of
FPPS (i.e. the same mechanism by which these
agents affect osteoclast function).69,70
Oesophageal cancer
Cases of oesophageal cancer in oral bisphospho-
nate-treated patients have been reported by an offi-
cial letter from the FDA.71 Twenty-three cases of
oesophageal cancer following alendronate use
were reported to the FDA between October 1995
and May 2008. Eight of these patients died. The
median time to diagnosis of oesophageal cancer
from the start of alendronate use was 2.1 years.
During the same period, a further 31 cases—of
which six were fatal—were reported in Europe and
Japan following alendronate use. Six of these cases
also involved use of risedronate, ibandronate, or eti-
dronate. Thus, physicians should avoid prescribing
oral bisphosphonates to patients with known risk
factors for oesophageal cancer, such as Barrett’s
oesophagus.71
However, these limited data should be interpreted
with caution due to the lack of a control group. Also,
the median time to diagnosis was too brief to be
suggestive of a causal relationship between the
drug and the disease,72,73 and little comparison is
provided in the form of expected rates of oesopha-
geal cancer in, for example, post-menopausal
women. In addition, no data on the patients’ med-
ical history are presented.74 Therefore, it is possible
that some or all of the affected patients had
pre-existing disease.
Retrospective studies of registry data, where
bisphosphonate-treated patients were compared
with bisphosphonate-naive patients, have since
shown that there is no increase in the incidence
rate of oesophageal cancer with bisphosphonate
use, and that there may even be a significant pro-
tective effect.75,76 Thus, it is clear that large RCTs are
required to further elucidate this relationship, with a
sufficient exposure time and follow-up, and with
analyses for confounding variables.
Mortality benefit
It has only recently become evident that the
reduction in fracture risk associated with effective
management of osteoporosis is associated with
a reduction in mortality. For example, in the
HORIZON-RFT trial, annual administration of
zoledronic acid was associated with a significant
28% reduction in all-cause mortality in patients
who had undergone surgical repair of hip fracture
prior to treatment initiation.41 This finding is sup-
ported by the results of a recent meta-analysis of
randomized, placebo-controlled trials in which pa-
tients with osteoporosis received approved doses of
medications with proven efficacy in preventing both
vertebral and non-vertebral fractures.77 Synthesis of
data from eight studies that involved administration
of risedronate, strontium ranelate, zoledronic
acid, or denosumab revealed that treatment was
associated with an 11% reduction in mortality
(P=0.036). This beneficial effect of therapy on mor-
tality was not related to either patient age or the
incidence of fracture (hip or non-vertebral), but
was most substantial in the trials with higher overall
mortality rates. This led the authors to conclude that
osteoporosis therapies with proven anti-fracture effi-
cacy reduce mortality in older, frailer individuals
who are at high risk of fracture.77
This summary of adverse event data shows that all
bisphosphonates are not the same regarding safety.
In particular, oral risedronate and alendronate differ
in some aspects from IV ibandronate and zoledronic
acid; for example, they are more associated with
gastrointestinal adverse events, while the latter are
more associated with the acute phase reaction.
Treatment decisions and selecting
the appropriate therapy
When pharmacological properties, efficacy and
safety are collectively taken into account, evidently
all bisphosphonates are not the same. The RAND
CER, WHO and ESCEO/IOF recommendations all
state that risedronate and alendronate provide com-
prehensive fracture protection.5–7 Yet clinical trial
data suggest that zoledronic acid provides the most
comprehensive fracture protection, and is the only
bisphosphonate with proven anti-fracture efficacy in
the post-hip fracture population.78 Furthermore, all
bisphosphonates reviewed in this article are highly
effective in preventing the most common type of
fracture—vertebral fracture79—in women with
PMO. Therefore, how does a clinician choose a
first-line treatment?
The answer is that all of the bisphosphonates re-
viewed in this article are a suitable first-line treat-
ment for women with PMO. The clinical data reveal
no evidence to suggest that a particular therapy
should be elevated to first-line status, or indeed rele-
gated to second- or third-line status. The clinical
decision on first-line treatment should therefore be
largely based on a combination of clinical judgment
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and, where appropriate, patient preference. Data
that should be borne in mind, however, are the
documented differences in efficacy and compliance
between generic and branded bisphosphonates.
For example, a recent retrospective study found
that 1 year of treatment with generic alendronate
was associated with significantly lower increases
in BMD at the lumbar spine (2.8%) and total hip
(1.5%) than treatment with branded alendronate
(Fosamax: 5.2 and 2.9%, respectively) or branded
risedronate (Actonel: 4.8 and 3.1%, respectively).80
The persistence of patients who received generic
alendronate (68% still taking treatment after 12
months) was also significantly lower than with
either of the branded products (Fosamax, 84%;
Actonel, 94%). This study was not designed to de-
termine the reasons why the BMD increases asso-
ciated with the generic product were 40–50% lower
than the branded products, although the difference
in persistence is likely to be a factor. These data
should be of concern to clinicians in countries
such as the UK, where the National Institute of
Health and Clinical Excellence guidance requires
patients to be prescribed alendronate in the first in-
stance. Clinicians are advised that alternative treat-
ments such as risedronate or etidronate should only
be prescribed if patients are intolerant of alendro-
nate or unable to comply with the dosing instruc-
tions.81 Differences between generic and branded
bisphosphonates led the National Osteoporosis
Foundation of South Africa to issue a statement in
2006 expressing concern that available information
on generic alendronate may not be sufficient to de-
termine its long-term efficacy and safety, and noting
that the South African Medicines Control Council
had placed alendronate on its ‘non-substitutable’
list for similar reasons.82 Until more data become
available, it therefore seems prudent to be cautious
in the prescription of generic bisphosphonates.
One of the main considerations faced by clin-
icians in determining which bisphosphonate to pre-
scribe is the mode of administration. The ability of a
patient to adhere to treatment regimens is an import-
ant factor in this choice. Oral bisphosphonates are
associated with similar costs to IV bisphosphonates
(although generic oral bisphosphonates are less ex-
pensive); however, oral products are associated with
poor compliance/adherence.83,84 Several studies
have shown that patients with high levels of adher-
ence to osteoporosis medication have significantly
lower fracture rates than those with low levels of
adherence, with risk reductions for overall fractures
averaging 20%.83,85–87 Thus, oral medications are
useful for patients who have disciplined lifestyles,
who are therefore more likely to be adherent to
treatment.
The IV bisphosphonates may improve adherence
to therapy, and they are useful for patients who are
unable or unwilling to take oral medications or who
have experienced a fracture while taking oral medi-
cations, as this is likely to be due to poor adherence.
There is evidence to show that it is safe to switch
from an oral to an IV bisphosphonate in this way.88
Adherence plays a vital role in the economics of
fracture protection. There is no real-life effectiveness
with oral bisphosphonates if compliance is <50%,
and typical compliance with oral bisphosphonates
over 2 years is just 43%.83 The difference in adher-
ence between a yearly and weekly administered
treatment would result in fewer fractures with IV
compared with oral bisphosphonates and therefore
lower real-life costs.89 Cost calculations of poor ad-
herence and ‘wasted’ oral bisphosphonates led
Sheehy et al.90 to suggest that bisphosphonates
with less frequent dosing regimens, such as a
once-yearly medication, should be investigated fur-
ther as these would constitute the equivalence of
‘perfect adherence with weekly or monthly present-
ly available oral bisphosphonates’. In fact, IV
bisphosphonates are proven to be more cost effect-
ive than branded oral bisphosphonates in women
with PMO.90
Another crucial aspect of choosing a bisphospho-
nate is the patient’s medical history. Oral bispho-
sphonates should be used with caution in patients
with a history of oesophageal disorders that delay
oesophageal transit or emptying, or who have a his-
tory of oesophageal or upper gastrointestinal prob-
lems. The patient must also be capable of
maintaining an upright position for at least 30min
after taking the tablet.
Ibandronate should not be used in patients with a
history of, or risk factors for, non-vertebral (including
hip) fractures, as there is no clinical evidence to
support its use in such patients. Similarly, clinical
evidence suggests that in patients with a history of,
or at high risk of, hip fracture, alendronate and zole-
dronic acid are more efficacious than risedronate in
reducing hip fracture risk.17,18,20–22
The only data that we currently have that give
efficacy comparisons among bisphosphonates are
from post-marketing surveillance studies. As dis-
cussed above, the VIBE study found a significantly
lower risk of vertebral fracture in patients treated
with monthly ibandronate than in those who
received weekly alendronate/risedronate25 and the
REAL study showed that weekly risedronate is asso-
ciated with significantly lower incidences of
non-vertebral and hip fracture than weekly
alendronate.26
Another major factor in treatment choice is pa-
tient preference. In patients who are already taking
296 R. Rizzoli
a number of concomitant medications, or who have
lifestyles that do not accommodate frequent, strict
dosing regimens, a quarterly or once-yearly intra-
venous medication may be welcomed. Conversely,
many patients prefer oral medications and the con-
trol associated with it. A minority of patients—
approximately one in five—may have a fear of nee-
dles91,92 and therefore avoid IV options, although
this is more than twice as likely to occur in people
aged under 50 years than those over 50.92 Clinical
trials of bisphosphonate therapy have shown that
annual IV dosing is generally preferred by patients
to weekly oral regimens. In a 24-week RCT
that compared annual infusion of zoledronic acid
5mg and oral weekly alendronate 70mg in
post-menopausal women with low bone density,
66.4% of the patients who completed an
end-of-study questionnaire expressed a preference
for the once-yearly IV infusion, compared with
19.7% who preferred a once-weekly pill. Just
13.9% considered both treatment modalities
equal.24 Similarly in a 1-year RCT of post-
menopausal women with low BMD on alendronate
who were randomized to continue with oral weekly
alendronate 70mg or switch to zoledronic acid 5mg
infusion, 78.7% of patients preferred a once-yearly
infusion (Figure 3).88
Conclusions
International treatment guidelines recommend the
use of bisphosphonates as first-line therapy in pa-
tients with osteoporosis, with the prime objective
of reducing the number of osteoporotic fractures.
Selection of a specific bisphosphonate for treating
PMO should be based on a review of efficacy
data, risk profile, inclination of the patient and the
cost-effectiveness of the therapy.93 The advantages
and disadvantages of each viable option should
always be presented to the patient and the import-
ance of the patient’s preferences acknowledged.
Overall, all bisphosphonates are potential first-line
treatments for PMO. Their efficacy and favourable
risk–benefit profile, as well as their possible mortal-
ity benefit, have set high standards in the field, such
that emerging drugs for PMO must have equal or
better benefits. Ultimately, the choice of bispho-
sphonate treatment is largely dependent on the in-
dividual patient.
Acknowledgements
Sola Neunie of BioScience Communications,
London provided editorial support during the prep-
aration of this manuscript, which was funded by
Novartis Pharmaceuticals.
Funding
Novartis Pharmaceuticals, who reviewed the outline
and first draft of this article. R.R. did not receive a fee
for the authorship of this article.
Conflict of interest: R.R. has attended advisory
boards and received lecturing fees from Servier,
Novartis, Eli Lilly, Amgen, Roche, Nycomed,
Merck Sharp and Dohme and Danone.
References
1. International Osteoporosis Foundation 2009. About
Osteoporosis: Prevention. [http://www.iofbonehealth.org/
patients-public/about-osteoporosis/prevention.html]
Accessed 27 October 2010.
2. European Medicines Agency 2006. Guideline on the
Evaluation of Medicinal Products in the Treatment of
Primary Osteoporosis. CPMP/EWP/552/95 Rev. 2. [http://
www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500003405.pdf] Accessed
27 October 2010.
3. Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J,
Park RE. A method for the detailed assessment of the appro-
priateness of medical technologies. Int J Technol Assess
Health Care 1986; 2:53–63.
4. Naylor CD. What is appropriate care? N Engl J Med 1998;
338:1918–20.
5. MacLean C, Newberry S, Maglione M, McMahon M,
Ranganath V, Suttorp M, et al. Systematic review: com-
parative effectiveness of treatments to prevent fractures in
men and women with low bone density or osteoporosis.
Ann Intern Med 2008; 148:197–213.
6. World Health Organization 2003. Prevention and
Management of Osteoporosis. WHO Technical Report
Figure 3. Patient preference for once-yearly intravenous
therapy.24,88 Two separate studies have demonstrated
that the majority of post-menopausal women with low
bone density prefer an annual intravenous treatment to
once-weekly oral treatment.
Bisphosphonates for PMO 297
Series 921. [http://whqlibdoc.who.int/trs/who_trs_921.pdf]
Accessed 27 October 2010.
7. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY,
Borgstrom F, et al. European guidance for the diagnosis
and management of osteoporosis in postmenopausal
women. Osteoporos Int 2008; 19:399–428.
8. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S,
Wu W, et al. Novel insights into actions of bisphosphonates
on bone: differences in interactions with hydroxyapatite.
Bone 2006; 38:617–27.
9. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms
of action of bisphosphonates: similarities and differences and
their potential influence on clinical efficacy. Osteoporos Int
2008; 19:733–59.
10. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM,
Poulter CD, et al. Structure-activity relationships for inhib-
ition of farnesyl diphosphate synthase in vitro and inhibition
of bone resorption in vivo by nitrogen-containing bispho-
sphonates. J Pharmacol Exp Ther 2001; 296:235–42.
11. Mitchell DY, Barr WH, Eusebio RA, Stevens KA, Duke FP,
Russell DA, et al. Risedronate pharmacokinetics and intra-
and inter-subject variability upon single-dose intravenous
and oral administration. Pharm Res 2001; 18:166–70.
12. Roche Registration Limited. Bonviva Summary of Product
Characteristics. 2010. [http://www.ema.europa.eu/docs/
en_GB/document_library/EPAR_-_Product_Information/
human/000501/WC500052652.pdf] Accessed 12 January
2011.
13. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK,
McCloskey EV, et al. Elimination and biochemical responses
to intravenous alendronate in postmenopausal osteoporosis.
J Bone Miner Res 1997; 12:1700–7.
14. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S,
et al. Pharmacokinetics and pharmacodynamics of zoledro-
nic acid in cancer patients with bone metastases. J Clin
Pharmacol 2002; 42:1228–36.
15. Gertz BJ, Holland SD, Kline WF, Matuszewski BK,
Freeman A, Quan H, et al. Studies of the oral bioavailability
of alendronate. Clin Pharmacol Ther 1995; 58:288–98.
16. Tanko LB, McClung MR, Schimmer RC, Mahoney P,
Christiansen C. The efficacy of 48-week oral ibandronate
treatment in postmenopausal osteoporosis when taken
30 versus 60minutes before breakfast. Bone 2003;
32:421–6.
17. Black DM, Cummings SR, Karpf DB, Cauley JA,
Thompson DE, Nevitt MC, et al. Randomised trial of effect
of alendronate on risk of fracture in women with existing
vertebral fractures. Fracture Intervention Trial Research
Group. Lancet 1996; 348:1535–41.
18. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S,
Cauley JA, et al. Once-yearly zoledronic acid for treatment
of postmenopausal osteoporosis. N Engl J Med 2007;
356:1809–22.
19. Chesnut III CH, Skag A, Christiansen C, Recker R,
Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate
administered daily or intermittently on fracture risk in
postmenopausal osteoporosis. J Bone Miner Res 2004;
19:1241–9.
20. Cummings SR, Black DM, Thompson DE, Applegate WB,
Barrett-Connor E, Musliner TA, et al. Effect of alendronate
on risk of fracture in women with low bone density but
without vertebral fractures: results from the Fracture
Intervention Trial. JAMA 1998; 280:2077–82.
21. Harris ST, Watts NB, Genant HK, McKeever CD,
Hangartner T, Keller M, et al. Effects of risedronate treatment
on vertebral and nonvertebral fractures in women with post-
menopausal osteoporosis: a randomized controlled trial.
Vertebral Efficacy with Risedronate Therapy (VERT) Study
Group. JAMA 1999; 282:1344–52.
22. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C,
Brandi ML, et al. Randomized trial of the effects of risedro-
nate on vertebral fractures in women with estab-
lished postmenopausal osteoporosis. Vertebral Efficacy with
Risedronate Therapy (VERT) Study Group. Osteoporos Int
2000; 11:83–91.
23. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P,
Broy S, et al. Treatment with once-weekly alendronate 70mg
compared with once-weekly risedronate 35mg in women
with postmenopausal osteoporosis: a randomized double-
blind study. J Bone Miner Res 2005; 20:141–51.
24. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single
zoledronic acid infusion reduces bone resorption markers
more rapidly than weekly oral alendronate in postmenopau-
sal women with low bone mineral density. Bone 2007;
40:1238–43.
25. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA,
Barr CE, et al. Risk of fracture in women treated with monthly
oral ibandronate or weekly bisphosphonates: the eValuation
of IBandronate Efficacy (VIBE) database fracture study. Bone
2009; 44:758–65.
26. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R.
Effectiveness of bisphosphonates on nonvertebral and hip
fractures in the first year of therapy: the risedronate and
alendronate (REAL) cohort study. Osteoporos Int 2007;
18:25–34.
27. Ringe JD, Doherty JG. Absolute risk reduction in osteopor-
osis: assessing treatment efficacy by number needed to treat.
Rheumatol Int 2010; 30:863–9.
28. Christensen PM, Kristiansen IS. Number-needed-to-treat
(NNT)–needs treatment with care. Basic Clin Pharmacol
Toxicol 2006; 99:12–6.
29. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S,
Quandt SA, et al. Effects of continuing or stopping alendro-
nate after 5 years of treatment: the Fracture Intervention Trial
Long-term Extension (FLEX): a randomized trial. JAMA 2006;
296:2927–38.
30. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG,
Roux C, et al. Effect of risedronate on the risk of hip fracture
in elderly women. Hip Intervention Program Study Group.
N Engl J Med 2001; 344:333–40.
31. Genant HK, Wu CY, van KC, Nevitt MC. Vertebral fracture
assessment using a semiquantitative technique. J Bone Miner
Res 1993; 8:1137–48.
32. Smith-Bindman R, Cummings SR, Steiger P, Genant HK. A
comparison of morphometric definitions of vertebral fracture.
J Bone Miner Res 1991; 6:25–34.
33. Merck Sharp & Dohme Limited. Fosamax Summary of
Product Characteristics. 2010. [http://www.medicines
.org.uk/emc/medicine/1175/SPC/Fosamax/] Accessed 12
January 2011.
34. Miller PD, McClung MR, Macovei L, Stakkestad JA,
Luckey M, Bonvoisin B, et al. Monthly oral ibandronate
298 R. Rizzoli
therapy in postmenopausal osteoporosis: 1-year results from
the MOBILE study. J Bone Miner Res 2005; 20:1315–22.
35. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ,
Silverman SL, et al. Efficacy and tolerability of once-monthly
oral ibandronate in postmenopausal osteoporosis: 2 year
results from the MOBILE study. Ann Rheum Dis 2006;
65:654–61.
36. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H,
Bell NH, et al. Effect of oral alendronate on bone mineral
density and the incidence of fractures in postmenopausal
osteoporosis. The Alendronate Phase III Osteoporosis
Treatment Study Group. N Engl J Med 1995; 333:1437–43.
37. Novartis Pharma Stein AG. Reclast (Zoledronic Acid)
Injection Prescribing Information. 2010. [http://
www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf]
Accessed 12 January 2011.
38. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-
bisphosphonates block retinoblastoma phosphorylation and
cell growth by inhibiting the cholesterol biosynthetic path-
way in a keratinocyte model for esophageal irritation. Mol
Pharmacol 2001; 59:193–202.
39. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L,
Battistoni F, et al. Fever after zoledronic acid administration
is due to increase in TNF-alpha and IL-6. J Interferon
Cytokine Res 2003; 23:649–54.
40. Thompson K, Rogers MJ. Statins prevent bisphosphonate-
induced gamma, delta-T-cell proliferation and activation
in vitro. J Bone Miner Res 2004; 19:278–88.
41. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD,
Pieper CF, Mautalen C, et al. Zoledronic acid and clinical
fractures and mortality after hip fracture. N Engl J Med 2007;
357:1799–809.
42. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM.
Characterization of and risk factors for the acute-phase re-
sponse after zoledronic acid. J Clin Endocrinol Metab 2010;
95:4380–7.
43. Cummings SR, Schwartz AV, Black DM. Alendronate and
atrial fibrillation. N Engl J Med 2007; 356:1895–6.
44. Camm JA. Review of the cardiovascular safety of zoledronic
acid and other bisphosphonates for the treatment of osteo-
porosis. Clin Ther 2010; 32:426–36.
45. Chapurlat RD. Treatment of osteoporosis with annual iv zole-
dronic acid: effects on hip fracture. Ther Clin Risk Manag
2009; 5:169–75.
46. Sorensen HT, Christensen S, Mehnert F, Pedersen L,
Chapurlat RD, Cummings SR, et al. Use of bisphosphonates
among women and risk of atrial fibrillation and flutter:
population based case-control study. Br Med J 2008;
336:813–6.
47. Kennel KA, Drake MT. Adverse effects of bisphosphonates:
implications for osteoporosis management. Mayo Clin Proc
2009; 84:632–7.
48. US Food and Drug Administration 2008. Safety alerts for
human medical products. Bisphosphonates marketed as
alendronate (Fosamax, Fosamax Plus D), etidronate
(Didronel), ibandronate (Boniva), pamidronate (Aredia), rise-
dronate (Actonel, Actonel w/calcium), tiludronate (Skelid),
zoledronic acid (Reclast, Zometa). [http://www.fda.gov/
Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman
MedicalProducts/ucm079352.htm] Accessed 27 October
2010.
49. Bilezikian JP. Osteonecrosis of the jaw–do bisphosphonates
pose a risk? N Engl J Med 2006; 355:2278–81.
50. Khan AA, Sandor GKB, Dore E, Morrison AD, Alsahli M,
Amin F, et al. Bisphosphonate associated osteonecrosis of
the jaw. J Rheumatol 2009; 36:478–90.
51. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF,
Felsenberg D, et al. Osteonecrosis of the jaw and
bisphosphonate treatment for osteoporosis. Bone 2008;
42:841–7.
52. Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR,
Leung PC, et al. Incidence of osteonecrosis of the jaw in
women with postmenopausal osteoporosis in the health
outcomes and reduced incidence with zoledronic acid
once yearly pivotal fracture trial. J Am Dent Assoc 2008;
139:32–40.
53. Armamento-Villareal R, Napoli N, Diemer K, Watkins M,
Civitelli R, Teitelbaum S, et al. Bone turnover in bone biop-
sies of patients with low-energy cortical fractures receiving
bisphosphonates: a case series. Calcif Tissue Int 2009;
85:37–44.
54. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT,
et al. Subtrochanteric insufficiency fractures in patients on
alendronate therapy: a caution. J Bone Joint Surg Br 2007;
89:349–53.
55. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P,
Peter R. Low-energy femoral fractures associated with the
long-term use of bisphosphonates: a case series from a
Swiss university hospital. Drug Saf 2009; 32:775–85.
56. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging
pattern of subtrochanteric stress fractures: a long-term com-
plication of alendronate therapy? Injury 2008; 39:224–31.
57. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-
Osula F, Steele B, et al. Association of low-energy femoral
fractures with prolonged bisphosphonate use: a case control
study. Osteoporos Int 2009; 20:1353–62.
58. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F,
Lorich DG. Low-energy femoral shaft fractures associated
with alendronate use. J Orthop Trauma 2008; 22:346–50.
59. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA,
Pak CY. Severely suppressed bone turnover: a potential com-
plication of alendronate therapy. J Clin Endocrinol Metab
2005; 90:1294–301.
60. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R,
Bucci-Rechtweg C, et al. Bisphosphonates and fractures of
the subtrochanteric or diaphyseal femur. N Engl J Med 2010;
362:1761–71.
61. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of
the femur and bisphosphonate therapy. A systematic review
of case/case series studies. Bone 2010; 47:169–80.
62. European Medicines Agency 2009. Assessment report for
Fosavance. EMEA/CHMP/188952/2009. [http://www.ema.
europa.eu/docs/en_GB/document_library/EPAR_-_
Assessment_Report_-_Variation/human/000619/
WC500024252.pdf] Accessed 27 October 2010.
63. Merck Sharp and Dohme Limited. Fosavance Summary of
Product Characteristics. 2010. [http://www.medicines
.org.uk/emc/medicine/16569/SPC/] Accessed 12 January
2011.
64. Rizzoli R, A˚kesson K, Bouxsein M, Kanis J, Napoli N,
Papapoulos S, et al. Subtrochanteric fractures after long-term
treatment with bisphosphonates: a European Society on
Bisphosphonates for PMO 299
Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis, and International Osteoporosis Foundation
Working Group Report. Osteoporos Int 2010.
65. von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone
pain: treatment options with an emphasis on bisphospho-
nates. Support Care Cancer 2008; 16:1105–15.
66. Procter and Gamble Pharmaceuticals. Actonel Summary
of Product Characteristics. 2010. [http://www.medicines
.org.uk/EMC/medicine/11591/SPC/
Actonel+Once+a+Week+35mg+film+coated+tablets./]
Accessed 12 January 2011.
67. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A,
Abrams K, Mesenbrink P, et al. Renal safety of annual zole-
dronic acid infusions in osteoporotic postmenopausal
women. Kidney Int 2008; 74:641–8.
68. US Food and Drug Administration 2009. Drug Safety
Newsletter. Vol. 2, Number 2. [http://www.fda.gov/down-
loads/Drugs/DrugSafety/DrugSafetyNewsletter/UCM168579.
pdf] Accessed 27 October 2010.
69. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bispho-
sphonate renal safety. Oncologist 2005; 10(Suppl. 1):3–7.
70. Luhe A, Kunkele KP, Haiker M, Schad K, Zihlmann C,
Bauss F, et al. Preclinical evidence for nitrogen-containing
bisphosphonate inhibition of farnesyl diphosphate (FPP) syn-
thase in the kidney: implications for renal safety. Toxicol In
Vitro 2008; 22:899–909.
71. Wysowski DK. Reports of esophageal cancer with oral
bisphosphonate use. N Engl J Med 2009; 360:89–90.
72. Hofbauer LC, Miehlke S. More on reports of esophageal
cancer with oral bisphosphonate use. N Engl J Med 2009;
360:1790–2.
73. Robins HI, Holen KD. More on reports of esophageal cancer
with oral bisphosphonate use. N Engl J Med 2009;
360:1790–2.
74. Siris ES, Oster MW, Bilezikian JP. More on reports of esopha-
geal cancer with oral bisphosphonate use. N Engl J Med
2009; 360:1791–2.
75. Abrahamsen B, Eiken P, Eastell R. More on reports of esopha-
geal cancer with oral bisphosphonate use. N Engl J Med
2009; 360:1789.
76. Solomon DH, Patrick A, Brookhart MA. More on reports of
esophageal cancer with oral bisphosphonate use. N Engl J
Med 2009; 360:1789–90.
77. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of
osteoporosis treatment on mortality: a meta-analysis. J Clin
Endocrinol Metab 2010; 95:1174–81.
78. Rizzoli R. Zoledronic acid for the treatment and prevention of
primary and secondary osteoporosis. Ther Adv Musculoskel
Dis 2010; 2:3–16.
79. National Osteoporosis Foundation. America’s bone health:
the state of osteoporosis and low bone mass in our nation.
NOF 2002; 2:5–7.
80. Ringe JD, Moller G. Differences in persistence, safety and
efficacy of generic and original branded once weekly bispho-
sphonates in patients with postmenopausal osteoporosis:
1-year results of a retrospective patient chart review analysis.
Rheumatol Int 2009; 30:213–21.
81. National Institute for Health and Clinical Excellence 2010
Final appraisal determination. Alendronate, etidronate,
risedronate, raloxifene and strontium ranelate for the pri-
mary prevention of osteoporotic fragility fractures in postme-
nopausal women (amended). NICE Technology Appraisal
Guidance 160 (Amended). [http://www.nice.org.uk/niceme-
dia/live/11746/47176/47176.pdf] Accessed 27 October
2010.
82. National Osteoporosis Foundation of South Africa. Use of
generic alendronate in the treatment of osteoporosis.
S Afr Med J 2006; 96:696–7.
83. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN,
Abbott TA, et al. Adherence to bisphosphonate therapy
and fracture rates in osteoporotic women: relationship to
vertebral and nonvertebral fractures from 2 US claims data-
bases. Mayo Clin Proc 2006; 81:1013–22.
84. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M,
Polinski JM, et al. Compliance with osteoporosis medica-
tions. Arch Intern Med 2005; 165:2414–9.
85. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The
impact of compliance with osteoporosis therapy on fracture
rates in actual practice. Osteoporos Int 2004; 15:1003–8.
86. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance
with osteoporosis treatment and its consequences in a man-
aged care population. Bone 2006; 38:922–8.
87. van den Boogaard CH, Breekveldt-Postma NS,
Borggreve SE, Goettsch WG, Herings RM. Persistent
bisphosphonate use and the risk of osteoporotic fractures
in clinical practice: a database analysis study. Curr Med Res
Opin 2006; 22:1757–64.
88. McClung M, Recker R, Miller P, Fiske D, Minkoff J,
Kriegman A, et al. Intravenous zoledronic acid 5mg in
the treatment of postmenopausal women with low bone
density previously treated with alendronate. Bone 2007;
41:122–8.
89. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I,
Francis RM, et al. Secondary prevention of osteoporosis:
when should a non-vertebral fracture be a trigger for
action? QJM 2001; 94:575–97.
90. Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence
to weekly oral bisphosphonate therapy: cost of wasted
drugs and fractures. Osteoporos Int 2009; 20:1583–94.
91. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in
young adults: prevalence and associations. Am J Trop
Med Hyg 2003; 68:341–4.
92. Wright S, Yelland M, Heathcote K, Ng SK, Wright G. Fear of
needles–nature and prevalence in general practice. Aust
Fam Physician 2009; 38:172–6.
93. Owens G, Jackson R, Lewiecki EM. An integrated approach:
bisphosphonate management for the treatment of osteopor-
osis. Am J Manag Care 2007; 13(Suppl 11):S290–308.
94. Catterall JB, Cawston TE. Drugs in development: bispho-
sphonates and metalloproteinase inhibitors. Arthritis Res
Ther 2003; 5:12–24.
300 R. Rizzoli
